Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 301–400 of 1,008
Masuishi, T., Taniguchi, H., Hamauchi, S., Komori, A., Kito, Y., Narita, Y., Tsushima, T., Ishihara, M., Todaka, A., Tanaka, T., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.019 · Cited by 75
“nical Colorectal Cancer Month 2016 oxaliplatin, irinotecan, anti-VEGF antibodies, and anti-EGFR antibodies (if KRAS exon 2 wild-type tumor); (3) no previous treatment with regorafenib or TAS-102; (4) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2; and (5) adequate bone marrow, hepatic, and r…”
BackgroundInfluentialBahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 78
“Further subanalyses supported the benefit of cetuximab in patients with a RAS wild-type tumors (Douillard et al., 2013).”
BackgroundResultGinghină, O., Hudiță, A., Zamfir, M., Spânu, A., Mardare, M., Bondoc, I., Buburuzan, L., Georgescu, S. E., Costache, M., Negrei, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856575 · Cited by 80
Oba, M., Hasegawa, K., Shindoh, J., Yamashita, S., Sakamoto, Y., Makuuchi, M., & Kokudo, N. (2015) · Surgery · doi:10.1016/j.surg.2015.09.003 · Cited by 80
Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation
Fessler, E., & Medema, J. P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.008 · Cited by 92
Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-309026 · Cited by 73
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
“In contrast, in a first line setting, BRAFV600E mutation was not identified as a negative predictive biomarker of response to cetuximab or panitumumab added on top to FOLFOX or FOLFIRI, but rather a poor prognostic biomarker [46,47].”
BackgroundSelf-citationLi, T. X., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00014-6 · Cited by 73
Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
Johnson, D. B., Smalley, K. S. M., & Sosman, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3270 · Cited by 87
Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
Hahne, J. C., & Valeri, N. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00226 · Cited by 75
Élez, E., Argilés, G., & Tabernero, J. M. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0369-x · Cited by 83
Self-citationGyawali, B., de Vries, E. G. E., Dafni, U. G., Amaral, T. M. S., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez‐Roca, C., Kiesewetter, B., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100117 · Cited by 79
Self-citationGrenader, T., Nash, S., Adams, R., Kaplan, R. S., Fisher, D. J., Maughan, T., & Bridgewater, J. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.23 · Cited by 72
Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer
Gallo, G., Vescio, G., Paola, G. D., & Sammarco, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112295 · Cited by 75
“Aflibercept is a recombinant fusion protein composed of the constant Fc domain of human IgG and the second and third immunoglobulin domains of VEGFR-1 and VEGFR-2, respectively.”
BackgroundMolecularly targeted therapies in cancer: a guide for the nuclear medicine physician
Lheureux, S., Denoyelle, C., Ohashi, P. S., Bono, J. S. D., & Mottaghy, F. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3695-3 · Cited by 81
“Cetuximab and panitumumab are monoclonal antibodies that target ErbB1 and are used in the treatment of colorectal cancer [54, 55].”
Schrock, A. B., Pavlick, D., Klempner, S. J., Chung, J. H., Forcier, B., Welsh, A., Young, L., Leyland-Jones, B., Bordoni, R., Carvajal, R. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3103 · Cited by 71
“Extended RAS and BRAF testing is widely performed in colorectal carcinoma to guide the use of anti-EGFR antibody therapies, which have shown particular efficacy in patients with tumors wild type for KRAS, NRAS, and BRAF mutations (1, 2).”
BackgroundWong, N. A. C. S., de Castro, D. G., Salto‐Tellez, M., Butler, R., Díaz‐Cano, S. J., Ilyas, M., Newman, W. G., Shaw, E. C., Tanière, P., & Walsh, S. V. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202467 · Cited by 78
Molecular Testing for Gastrointestinal Cancer
Lee, H. S., Kim, W. H., Kwak, Y., Koh, J., Bae, J. M., Kim, K., Chang, M. S., Han, H. S., Kim, J. M., Kim, H. W., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.01.24 · Cited by 73
“RAS mutation analysis results are critical for predicting resistance to epidermal growth factor receptor (EGFR) inhibitors in metastatic CRC patients, increasing the importance of molecular diagnosis in CRCs.(6) The detection of Epstein-Barr virus (EBV) by in situ hybridization (ISH) has enabled the identification of…”
BackgroundInfluentialMatos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez-Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 68
Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
Aparicio, J., Esposito, F. M., Serrano, S., Falcó, E., Escudero, P., Ruiz‐Casado, A., Manzano, H., & Montés, A. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123889 · Cited by 80
“The addition of cetuximab or panitumumab to either FOLFIRI or FOLFOX significantly increases patient OS from 20 to 26–28 months [15,18].”
BackgroundLiquid Biopsy to Identify Actionable Genomic Alterations
Ou, S. I., Nagasaka, M., & Zhu, V. W. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199765 · Cited by 78
Targeting BRAF and RAS in Colorectal Cancer
Bellio, H., Fumet, J.-D., & Ghiringhelli, F. (2021) · Cancers · doi:10.3390/cancers13092201 · Cited by 76
“In a pooled analysis of resected stage III colon cancer patients receiving adjuvant FOLFOX in the PETACC08 and N0147 trials, BRAF or KRAS mutations were found to be independently associated with a shorter time to recurrence and poorer overall survival in patients with MSS status [29].”
BackgroundInfluentialPan, W., Cheng, Y., Zhang, H., Liu, B., Mo, X., Li, T., Li, L., Cheng, X., Zhang, L., Ji, J., et al. (2014) · Scientific Reports · doi:10.1038/srep06812 · Cited by 76
Thomsen, M., Skovlund, E., Sørbye, H., Bolstad, N., Nustad, K., Glimelius, B. L. G., Pfeiffer, P., Kure, E. H., Johansen, J. S., Tveit, K. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0115-9 · Cited by 75
Khan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 75
Self-citationSánchez-Martín, F. J., Bellosillo, B., Gelabert-Baldrich, M., Dalmases, A., Cañadas, I., Vidal, J., Martinez, A., Argilés, G., Siravegna, G., Arena, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2400 · Cited by 68
“Approved monoclonal antibodies (mAb) directed against the epidermal growth factor receptor (EGFR) --cetuximab and panitumumab-- provide significant survival benefit to patients with wild-type KRAS and NRAS metastatic colorectal cancer (MCRC) and are now standard components of treatment regimens for these patients, eit…”
BackgroundSelf-citationShitara, K., Yonesaka, K., Denda, T., Yamazaki, K., Moriwaki, T., Tsuda, M., Takano, T., Okuda, H., Nishina, T., Sakai, K., et al. (2016) · Cancer Science · doi:10.1111/cas.13098 · Cited by 68
Bartolini, A., Cardaci, S., Lamba, S., Oddo, D., Marchiò, C., Cassoni, P., Amoreo, C. A., Corti, G., Testori, A., Bussolino, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2664 · Cited by 74
“A large body of prior work has shown that mutations in EGFR downstream effectors, such as KRAS (3), NRAS (4), BRAF (5), and PI3K (6), lead to a constitutive activation of the signaling pathway, thus bypassing a therapeutic block of the receptor.”
BackgroundKim, T. W., Elme, A., Kusic, Z., Park, J. O., Udrea, A. A., Kim, S. Y., Ahn, J. B., Valencia, R. V., Krishnan, S., Bilic, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.309 · Cited by 66
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., Grob, T., Alawi, M., Indenbirken, D., Kriegs, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3574 · Cited by 67
“Resistance to these antibodies is mediated by mutations in downstream signaling molecules [18-21], with mutated RAS, which is currently the only validated and widely accepted molecular marker that predicts lack of response to EGFR antibodies and, therefore, guides treatment decisions in mCRC [20, 22-25].”
BackgroundKRASandBRAFgene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients
Ye, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i5.1595 · Cited by 71
Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.308 · Cited by 65
“Recently, minor RAS (KRAS exons 3 and 4 or NRAS exons 2, 3, and 4) mutations observed in B15–20% of mCRC with wild-type KRAS exon 2 cases have been validated as negative predictive biomarkers for antiEGFR antibody treatment (Douillard et al, 2013).”
Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach
Blanco, M., Concha, Á., Figueroa, A., Garrido, F., & Valladares‐Ayerbes, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613610 · Cited by 72
“In patients receiving FOLFOX4 plus panitumumab, any RAS mutations were negatively associated with outcomes [89].”
BackgroundNeerincx, M., Sie, D., van de Wiel, M. A., van Grieken, N. C. T., Burggraaf, J. D., Dekker, H., Eijk, P. P., Ylstra, B., Verhoef, C. K., Meijer, G. A., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.29 · Cited by 67
Stopfer, L. E., Flower, C. T., Gajadhar, A. S., Patel, B., Gallien, S., Lopez-Ferrer, D., & White, F. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3804 · Cited by 66
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 76
Self-citationTargeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors
Nakamura, Y., Ozaki, H., Ueno, M., Komatsu, Y., Yuki, S., Esaki, T., Taniguchi, H., Sunakawa, Y., Yamaguchi, K., Kato, K., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03244-8 · Cited by 75
Favorable Outcome After Repeat Resection for Colorectal Liver Metastases
Saiura, A., Yamamoto, J., Koga, R., Takahashi, Y., Takahashi, M., Inoue, Y., Ono, Y., & Kokudo, N. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3863-7 · Cited by 65
Duwe, G., Knitter, S., Pesthy, S., Beierle, A. S., Bahra, M., Schmelzle, M., Schmuck, R. B., Lohneis, P., Raschzok, N., Öllinger, R., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.05.008 · Cited by 69
Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., García, A., Alcaráz, A., Vega, S., Bueno, S., Tabernero, J. M., et al. (2023) · Cancers · doi:10.3390/cancers15164020 · Cited by 80
“Multiple clinical trials involving cetuximab and panitumumab have demonstrated that not only mutations in KRAS exon 2 but also mutations in exons 3 and 4, as well as exons 2, 3, and 4 of NRAS (expanded RAS analysis), are associated with a lack of response to anti-EGFR monoclonal antibodies [106,108].”
BackgroundSelf-citationChen, J., Guo, F., Shi, X., Zhang, L., Zhang, A., Jin, H., & He, Y. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-802 · Cited by 63
“Furthermore, additional mutations, including KRAS mutations beyond exon 2 and NRAS mutations, will be analyzed in our cohorts, since current studies based on Western CRC patients seem to suggest that they may be prognostic for outcome and predictive for the efficacy of anti-EGFR therapies [45], and few data is availab…”
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen, R., Cervera, P., Svrcek, M., Pellat, A., Dreyer, C., de Gramont, A., & André, T. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0453-5 · Cited by 66
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice
Fassan, M., Scarpa, A., Remo, A., Maglio, G. D., Troncone, G., Marchetti, A., Doglioni, C., Ingravallo, G., Perrone, G., Parente, P., et al. (2020) · Pathologica · doi:10.32074/1591-951x-158 · Cited by 68
Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 73
Igarashi, H., Kurihara, H., Mitsuhashi, K., Ito, M., Okuda, H., Kanno, S., Naito, T., Yoshii, S., Takahashi, H., Kusumi, T., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4264-7 · Cited by 67
“between mutation in KRAS codons 61 or 146 and resistance to anti-EGFR therapeutics.(7,8,20) Moreover, as additional RAS-activating mutations, NRAS mutations have been reported to predict the response in patients with CRC treated with anti-EGFR therapy.”
BackgroundResultBartley, A. N., Hamilton, S. R., Alsabeh, R., Ambinder, E. P., Berman, M. A., Collins, E., Fitzgibbons, P. L., Gress, D. M., Nowak, J. A., Samowitz, W. S., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0231-cp · Cited by 68
“A recent study has shown that NRAS mutation, like KRAS mutation, has influence on response to anti-EGFR therapy.(12) Although more studies are needed, these findings may lead to broad KRAS and NRAS panels to include codons 12, 13, 61, and 146 of both genes.”
BackgroundMutational profiling of kinases in glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., Molenaar, R. J., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., Vandertop, W. P., Leenstra, S., Noorden, C. J. F. V., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-718 · Cited by 76
“various types of cancer [13-19].”
Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer
Wei, X. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18404 · Cited by 70
18F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status
Lovinfosse, P., Koopmansch, B., Lambert, F., Jodogne, S., Kustermans, G., Hatt, M., Visvikis, D., Seidel, L., Polus, M., Albert, A., et al. (2016) · The British Journal of Radiology · doi:10.1259/bjr.20160212 · Cited by 63
Passot, G., Denbo, J. W., Yamashita, S., Kopetz, S., Chun, Y. S., Maru, D. M., Overman, M. J., Brudvik, K. W., Conrad, C. H., Aloia, T. A., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.07.032 · Cited by 66
Palomba, G., Doneddu, V., Cossu, A., Paliogiannis, P., Manca, A., Casula, M., Colombino, M., Lanzillo, A., Defraia, E., Pazzola, A., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1053-z · Cited by 71
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw209 · Cited by 69
Zhang, R., Wang, Z., Yu, Q., Shen, J., He, W., Zhou, D., Yu, Q., Fan, J., Gao, S., & Duan, L. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14148 · Cited by 68
BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
van Brummelen, E. M. J., de Boer, A., Beijnen, J. H., & Schellens, J. H. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0031 · Cited by 68
“BRAF and RAS mutations are mutually exclusive, which highlights their functional importance [7].”
BackgroundYoshino, T., Muro, K., Yamaguchi, K., Nishina, T., Denda, T., Kudo, T., Okamoto, W., Taniguchi, H., Akagi, K., Kajiwara, T., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.007 · Cited by 63
“…method, pyrosequencing, allele-specific PCR, MALDI-TOF mass array, and BEAMing [bead, emulsion, amplification and magnetics] assay) have been developed (Diehl et al., 2008; Douillard et al., 2013; Heinemann et al., 2014; Maughan et al., 2011; Parsons et al., 2011; Parsons and Myers, 2013).”
BackgroundMethodResultInfluentialClinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis
Breuer, E., Hebeisen, M., Schneider, M. A., Roth, L., Pauli, C., Frischer-Ordu, K., Eden, J., Pache, B. C.-E., Steffen, T., Hübner, M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab001 · Cited by 68
Prognostic Role of KRAS, NRAS, BRAF and PIK3CA Mutations in Advanced Colorectal Cancer
Foltran, L., Maglio, G. D., Pella, N., Ermacora, P., Aprile, G., Masiero, E., Giovannoni, M., Iaiza, E., Cardellino, G. G., Lutrino, S. E., et al. (2015) · Future Oncology · doi:10.2217/fon.14.279 · Cited by 73
Santoro, V., Jia, R., Thompson, H., Nijhuis, A. M., Jeffery, R. E., Kiakos, K., Silver, A. R., Hartley, J. A., & Hochhauser, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv394 · Cited by 69
Cercek, A., Boucher, T. M., Gluskin, J. S., Aguiló, A., Chou, J. F., Connell, L. C., Capanu, M., Reidy‐Lagunes, D. L., D'Angelica, M. I., & Kemeny, N. E. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24399 · Cited by 64
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Nigro, C. L., Ricci, V., Vivenza, D., Granetto, C., Fabozzi, T., Miraglio, E., & Merlano, M. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6944 · Cited by 70
Historical perspective: Two decades of progress in treating metastatic colorectal cancer
Lee, R. M., Cardona, K., & Russell, M. C. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25431 · Cited by 66
“The patients with RAS‐mutated tumors do not benefit, and possibly are detrimentally affected by the addition of anti‐EGFR therapy to cytotoxic chemotherapy regimens, and these mutations are associated with innate or acquired resistance.(55,59-62) BRAF proto‐”
BackgroundExpanded RAS: Refining the Patient Population
Atreya, C. E., Corcoran, R. B., & Kopetz, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9325 · Cited by 68
“Among five trials of first-line therapy for mCRC, including FIRE-3, the prevalence of expanded RAS mutations in tumor specimens, previously determined to be wild type at exon 2 of KRAS, ranged from 15% to 27%.(12,15,16,19,20) Studies at both extremes of mutation prevalence used BEAMing (beads, emulsions, amplification…”
BackgroundPersonalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 66
“Similarly, mutation in KRAS outside of exon 2 and mutation in NRAS are predictive for poor response to EGFR-ab therapy [20,21].”
BackgroundHecht, J. R., Douillard, J., Schwartzberg, L. S., Grothey, A., Kopetz, S., Rong, A., Oliner, K. S., & Sidhu, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.008 · Cited by 68
“The primary findings from a randomized study (PRIME) assessing the efficacy of firstline panitumumab plus FOLFOX versus FOLFOX alone showed, consistent with other studies, that KRAS exon 2 mutations were a predictor of lack of response to panitumumab in patients with mCRC.(44) In the study’s primary analysis – which e…”
BackgroundResultInfluentialSelf-citationKrebs, M., Renehan, A. G., Backen, A. C., Gollins, S., Chau, I., Hasan, J., Valle, J. W., Morris, K. L., Beech, J., Ashcroft, L., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.006 · Cited by 61
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer
Zhang, C., Lv, J., Gong, L., Yu, L., Chen, X., Zhou, H., & Fan, L. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13090892 · Cited by 69
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 65
Perspectives of the Application of Liquid Biopsy in Colorectal Cancer
Ding, Y., Li, W., Wang, K., Xu, C., Hao, M., & Ding, L. (2020) · BioMed Research International · doi:10.1155/2020/6843180 · Cited by 64
“[99] KRAS, NRAS Bidirectional Sanger sequencing Therapy selection and monitoring”
BackgroundMethodHeinemann, V., Rivera, F., O’Neil, B. H., Stintzing, S., Koukakis, R., Terwey, J.-H., & Douillard, J. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.019 · Cited by 62
“Patients with these less common KRAS and NRAS mutations do not benefit from EGFRIs, and the effects of these mutations appear similar to those seen in KRAS exon 2 mutant mCRC [31,32].”
BackgroundSelf-citationReview of systemic therapies for locally advanced and metastatic rectal cancer.
Yaffee, P. M., Osipov, A., Tan, C. R. C., Tuli, R., & Hendifar, A. E. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2014.112 · Cited by 58
“org 4 as well as NRAS exons 2, 3, and 4 (117).”
BackgroundMethodInfluentialSegelov, E., Thavaneswaran, S., Waring, P. M., Desai, J., Robledo, K. P., Gebski, V. J., Elez, E., Nott, L. M., Karapetis, C. S., Lunke, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6843 · Cited by 59
Therapeutic inhibition of SGK1 suppresses colorectal cancer
Liang, X., Lan, C. B., Jiao, G., Fu, W., Long, X., An, Y., Wang, K., Zhou, J., Chen, T., Li, Y., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.184 · Cited by 60
MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing
Hempelmann, J. A., Scroggins, S. M., Pritchard, C. C., & Salipante, S. J. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.05.008 · Cited by 64
Rey, J., Launay‐Vacher, V., & Tournigand, C. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0333-x · Cited by 58
Sasaki, K., Margonis, G. A., Wilson, A., Kim, Y., Buettner, S., Andreatos, N., Gani, F., Amini, N., Spolverato, G., & Pawlik, T. M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5361-6 · Cited by 58
Toledo, R. A., Cubillo, A., Vega, E., Garralda, E., Álvarez-Gallego, R., Varga, L. U. D. L., Rodríguez-Pascual, J., Sánchez, G., Sarno, F., Prieto, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13311 · Cited by 63
“However, these patients ultimately progress, at least partially because of the emergence of mutations that occur in genes in the RAS pathway during treatment [2-5].”
BackgroundMultiple treatment lines and prognosis in metastatic colorectal cancer patients
Carlomagno, C., Stefano, A. D., Rosanova, M., Falco, S. D., Attademo, L., Fiore, G., & Placido, S. D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9748-7 · Cited by 62
Sundar, R., Huang, K. K., Qamra, A., Kim, K.-M., Kim, S. T., Kang, W. K., Tan, A., Lee, J., & Tan, P. B. O. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy550 · Cited by 61
“An example of commonly used negative predictive biomarkers in clinical practice in gastrointestinal cancers are RAS mutations to identify lack of benefit from antiEGFR therapy in metastatic colorectal cancer [18].”
MethodGiordano, G., Febbraro, A., Venditti, M., Campidoglio, S., Olivieri, N., Raieta, K., Parcesepe, P., Imbriani, G. C., Remo, A., & Pancione, M. (2014) · Gastroenterology Research and Practice · doi:10.1155/2014/526178 · Cited by 64
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Bupathi, M., & Wu, C. S.-Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.07.03 · Cited by 61
“The mutational status of KRAS and NRAS is indicative of worse prognosis, and its presence predicts the lack of efficacy of anti-epidermal growth factor receptor (anti-EGFR) antibody therapy (4,5).”
BackgroundSTAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Zulkifli, A., Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.010 · Cited by 61
Association between clinicopathological characteristics and RAS mutation in colorectal cancer
Rimbert, J., Tachon, G., Junca, A., Villalva, C., Karayan, L., & Tougeron, D. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.119 · Cited by 63
Hill, A. G., Findlay, M. P. N., Burge, M., Jackson, C., Alfonso, P., Samuel, L. M., Ganju, V., Karthaus, M., Amatu, A., Jeffery, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0646 · Cited by 63
Self-citationImmune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 56
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
Barber, L. J., Davies, M. N., & Gerlinger, M. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.12.001 · Cited by 62
Haley, L. M., Tseng, L., Zheng, G., Dudley, J. C., Anderson, D. A., Azad, N. S., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.86 · Cited by 60
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 69
Sastre, J., Massutí, B., Pulido, G., Guillén‐Ponce, C., Benavides, M., Manzano, J. L., Reboredo, M., Rivera, F., Grávalos, C., Safont, M. J., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.013 · Cited by 56
“Moreover, it can be administered every 2 weeks, and may be an option for selectedWTRAS frail patients [32].”
BackgroundMethodSelf-citationDeng, Y., Wang, L., Tan, S., Kim, G. P., Dou, R., Chen, D., Cai, Y., Fu, X., Wang, L., Zhu, J., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.006 · Cited by 72
Zhang, L., Castanaro, C., Luan, B., Yang, K., Fan, L., Fairhurst, J. L., Rafique, A., Potocky, T. B., Shan, J., Delfino, F. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1033 · Cited by 61
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Gaborit, N., Lindzen, M., & Yarden, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102809 · Cited by 60
Rolle, A.-F. L., Chiu, T. K., Fara, M. G., Shia, J., Zeng, Z., Weiser, M. R., Paty, P. B., & Chiu, V. K. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0555-4 · Cited by 58
“Dominant active KRAS mutation is the main oncogenic driver in approximately half of sporadic metastatic colorectal adenocarcinoma [19].”
BackgroundNeutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
Hamauchi, S., Yamazaki, K., Masuishi, T., Kito, Y., Komori, A., Tsushima, T., Narita, Y., Todaka, A., Ishihara, M., Yokota, T., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.005 · Cited by 64
Sequist, L. V. D., Gray, J. E., Harb, W. A., López-Chávez, A., Doebele, R. C., Modiano, M., Jackman, D. M., Baggstrom, M. Q., Atmaca, A., Felip, E., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0695 · Cited by 56
“This finding is not unique to targeting ErbB3 signaling nor specific to seribantumab; similar effects have been observed with several other receptor tyrosine kinase inhibitors, including the anti-insulin-like growth factor-1 receptor antibodies figitumumab [22] and dalotuzumab [23] the antiEGFR antibodies cetuximab [2…”
BackgroundStandardized Pathology Report for Colorectal Cancer, 2nd Edition
Kim, B., Kim, J. M., Kang, G. H., Chang, H. J., Kang, D. W., Kim, J. H., Bae, J. M., Seo, A. N., Park, H. S., Kang, Y. K., et al. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.09.28 · Cited by 66
“BRAF mutation analysis BRAF V600E mutations are observed in approximately two-thirds of MSI-high CRCs caused by MLH1 promoter hypermethylation, however, it never occurs in Lynch syndrome100.”
BackgroundInfluentialKRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 62
“Eventually, other hotspot mutations, KRAS exons 3 and 4 (comprising codons 59–61 and 117–146, respectively) and NRAS exons 2, 3 and 4 (comprising codons 12–13, 59–61 and 117–146, respectively), were found to be associated with clinical resistance to anti-EGFR treatment [23].”
BackgroundMorris, V. K., Lucas, F. A. S., Overman, M. J., Eng, C., Morelli, M. P., Jiang, Z., Luthra, R., Meric‐Bernstam, F., Maru, D. M., Scheet, P. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu252 · Cited by 58
“Previously classified as KRAS ‘wild-type’ tumors based on practices testing only for mutations in codons 12 or 13 of KRAS, these less common atypical RAS mutations have been shown to negate the presumed benefit of anti-EGFR therapies for patients with RAS wild-type tumors [9, 10].”
BackgroundActivation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis
Lu, M., Zessin, A. S., Glover, W., & Hsu, D. S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169439 · Cited by 56
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.